Addex Therapeutics Ltd ADXN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADXN is a good fit for your portfolio.
News
-
Addex to Present at the Swiss Biotech Day 2024
-
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
-
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
-
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
-
Addex to Present at the Bio-Europe Spring 2024 Conference
-
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
Trading Information
- Previous Close Price
- CHF 0.14
- Day Range
- CHF 0.11–0.14
- 52-Week Range
- CHF 0.04–0.26
- Bid/Ask
- CHF 0.12 / CHF 0.12
- Market Cap
- CHF 15.78 Mil
- Volume/Avg
- 1.4 Mil / 936,178
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.24
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
Valuation
|
Metric
|
ADXN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 14.81 |
Price/Sales | 6.24 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADXN
|
|---|---|
Quick Ratio | 1.39 |
Current Ratio | 1.46 |
Interest Coverage | −490.52 |
Quick Ratio
ADXN
Profitability
|
Metric
|
ADXN
|
|---|---|
Return on Assets (Normalized) | −149.29% |
Return on Equity (Normalized) | −261.29% |
Return on Invested Capital (Normalized) | −243.84% |
Return on Assets
ADXN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mrmbpzxhjl | Npn | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ddscmnwx | Wrjclq | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qbwlbnpg | Ytnwklm | $99.6 Bil | |
MRNA
| Moderna Inc | Ygqnkptn | Wcgd | $38.8 Bil | |
ARGX
| argenx SE ADR | Bkprzbnd | Gdt | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Rplkwrwf | Jzqts | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mlncbnhhp | Mxnmf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hbspmgmp | Xnfzpn | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qrnjpfklf | Dskllt | $12.4 Bil | |
INCY
| Incyte Corp | Dsqkvjvdm | Ndwbfv | $11.9 Bil |